Nasdaq
$0.9320▼ 2.25%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.5MShares out 8.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 1d agoAfter-hours26.10.24 06:276-KKey event#●●●#●●●#●●●
Immuron LtdBullish
Immuron Limited has reduced the maximum aggregate offering price available for sale under its existing At-The-Market (ATM) offering program to $2,006,769. This adjustment was formalized through a prospectus supplement filed on October 23, 2026, allowing the company to issue and sell ADSs at its discretion within this revised limit.…more
$0.9320-2.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 1d agoAfter-hours26.10.24 06:24424B5Offering
Immuron Ltd
Immuron has reduced the maximum aggregate offering price of securities available under its existing at-the-market (ATM) offering agreement with H.C. Wainwright to approximately $2,006,769. This adjustment is made to comply with the 12-month cumulative offering limit set forth in General Instruction I.B.5 of Form F-3.…more
$0.9320-2.25%vs prev closeView filingShare - 3d agoPre-market26.10.22 09:33filed6-KKey event
Immuron Ltd
Immuron Limited CEO Steven Lydeamore is scheduled to present at the Emerging Growth Conference on October 28, 2026, from 4:25 PM to 4:55 PM U.S. Eastern Time. The presentation will focus on the company's business strategy and the development progress of its infectious disease treatment pipeline, including Travelan and IMM-529.…more
$0.9320-2.25%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 07:27#●●●#●●●
Immuron CEO to Present at Emerging Growth Conference
Immuron CEO Steven Lydeamore is scheduled to present at the Emerging Growth Conference on October 28. This event serves as an opportunity to discuss the company's vision and pipeline, but contains no new financial or contractual updates.…more
$0.9320-2.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.13Pre-market26.10.13 19:06
●●●●●●●● ●●●●● ●●●●●●
Immuron's Phase 2 clinical trial data for its oral Travelan has been published in Scientific Reports, showing a 50% reduction in ETEC-related adverse events. However, the study failed to meet its primary efficacy endpoints, necessitating further large-scale clinical trials.…more
$0.9320-2.25%vs prev closeShareBenzinga - 10.13Pre-market26.10.13 19:00
●●●●●●●● ●●●●● ●●●●●●
Immuron published Phase 2 clinical trial results for its traveler's diarrhea drug, Travelan, in Scientific Reports. While the study showed favorable trends in some endpoints, it failed to meet its primary efficacy goals due to low statistical power.…more
$0.9320-2.25%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report